Xeris Biopharma (NASDAQ:XERS) Hits New 52-Week High – Time to Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)’s stock price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $5.07 and last traded at $5.03, with a volume of 3355595 shares traded. The stock had previously closed at $4.82.

Analysts Set New Price Targets

A number of research firms recently commented on XERS. Jefferies Financial Group reissued a “buy” rating and issued a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. HC Wainwright reissued a “buy” rating and issued a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Leerink Partners raised their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, March 7th. Piper Sandler reiterated a “neutral” rating and issued a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Finally, Craig Hallum increased their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a report on Friday, March 7th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.92.

Xeris Biopharma Trading Up 4.4 %

The business’s 50 day simple moving average is $3.71 and its 200 day simple moving average is $3.34. The firm has a market capitalization of $774.32 million, a PE ratio of -11.18 and a beta of 2.32.

Institutional Investors Weigh In On Xeris Biopharma

Several large investors have recently added to or reduced their stakes in XERS. Vanguard Group Inc. boosted its holdings in shares of Xeris Biopharma by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company’s stock worth $26,778,000 after purchasing an additional 133,738 shares during the period. Geode Capital Management LLC boosted its stake in Xeris Biopharma by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 3,351,426 shares of the company’s stock worth $11,364,000 after buying an additional 17,956 shares during the period. AIGH Capital Management LLC increased its position in Xeris Biopharma by 17.8% during the fourth quarter. AIGH Capital Management LLC now owns 2,574,846 shares of the company’s stock valued at $8,729,000 after acquiring an additional 389,192 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Xeris Biopharma by 31.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company’s stock valued at $7,115,000 after acquiring an additional 500,120 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Xeris Biopharma by 34.8% in the 4th quarter. Millennium Management LLC now owns 1,948,552 shares of the company’s stock worth $6,606,000 after acquiring an additional 502,853 shares during the last quarter. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.